Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and ISA101b in Recurrent/Metastatic HPV16 Cervical Cancer
NCT04646005Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of SLP-HPV-01 in Cervical Cancer (CC), sponsored by Regeneron Pharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
SLP-HPV-01
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04646005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646005.